Last reviewed · How we verify
Estradiol transdermal three 90 μL sprays
Estradiol binds to estrogen receptors (ERα and ERβ) throughout the body to restore circulating estrogen levels in postmenopausal women.
Estradiol binds to estrogen receptors (ERα and ERβ) throughout the body to restore circulating estrogen levels in postmenopausal women. Used for Vasomotor symptoms (hot flashes, night sweats) associated with menopause, Moderate to severe vulvovaginal atrophy associated with menopause.
At a glance
| Generic name | Estradiol transdermal three 90 μL sprays |
|---|---|
| Sponsor | Lumara Health, Inc. |
| Drug class | Hormone replacement therapy (HRT); estrogen |
| Target | Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ) |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Women's Health |
| Phase | Phase 3 |
Mechanism of action
Estradiol is a bioidentical estrogen that activates nuclear estrogen receptors in target tissues including the hypothalamus, pituitary, bone, cardiovascular system, and vaginal epithelium. The transdermal spray formulation delivers estradiol across the skin barrier, bypassing hepatic first-pass metabolism and providing sustained systemic hormone replacement. This restores estrogen-dependent physiological functions and alleviates symptoms associated with estrogen deficiency.
Approved indications
- Vasomotor symptoms (hot flashes, night sweats) associated with menopause
- Moderate to severe vulvovaginal atrophy associated with menopause
Common side effects
- Breast tenderness or pain
- Headache
- Nausea
- Application site reactions (erythema, irritation)
- Vaginal bleeding or spotting
- Fluid retention or bloating
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: